ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

2015 ACR/ARHP Annual Meeting: How Gender Differences Affect Pain

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—Men and women have different mechanisms that are at work in producing pain in rheumatic diseases—a little-studied and little-appreciated fact that is crucial to developing and using the right kinds of treatments, an expert in rheumatic disease pain said in a talk at the 2015 ACR/ARHP Annual Meeting. The lack of acknowledgment of this…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)GenderPainResearchRheumatic Diseaserheumatology

Bowing to Pressure, FDA to Reform Painkiller Approval Process

Toni Clarke  |  February 7, 2016

WASHINGTON (Reuters)—Bowing to pressure from lawmakers, Dr. Robert Califf, President Barack Obama’s nominee to lead the U.S. Food and Drug Administration (FDA), said on Thursday the agency would reform its process for approving opioid painkillers. Last month, Sen. Edward Markey (D-Ma.) placed a hold on Califf’s nomination, preventing it from being voted on by the…

Filed under:AnalgesicsDrug Updates

U.S. Sen. Markey Places Hold on Obama’s Nominee to Lead FDA

Toni Clarke  |  January 26, 2016

(Reuters)—U.S. Sen. Edward Markey (D-Mass.) said on Monday he has placed a hold on President Barack Obama’s nominee to head the U.S. Food and Drug Administration until the agency agrees to reform its process for approving opioid painkillers. Markey wants future opioid-approval matters to be reviewed by an FDA advisory committee, and believes the committee…

Filed under:AnalgesicsDrug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:AddictionApprovalsChildrenDrug SafetyFDAFood and Drug AdministrationhydrocodoneOpioidsPain

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Best Practices for Treating Non-Specific Low Back Pain

Emma W. White, PT, DPT, OCS, & Andy Bonin, MD  |  December 16, 2015

Low back pain (LBP) is one of the most common reasons for physician appointments. However, treatment results remain suboptimal, resulting in high rates of chronic pain, narcotic usage, surgery, depression and disability—all at great cost to individuals and the nation. One reason for this is the current practice of grouping all low back pain patients…

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:Clinical GuidelinesLBPlow back painpatient careTreatment

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2015

Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:belimumabLupus nephritisobinutuzumabOxycodoneSLEsystemic lupus erythematosus (SLE)

FDA Approves 2 Pain Drugs & New Gout Treatment on Road to Approval

Michele B. Kaufman, PharmD, BCGP  |  November 18, 2015

The FDA has approved two drugs designed to manage pain: buprenorphine for chronic pain and meloxicam capsules for OA pain. Lesurinad is also closer to FDA approval for treating gout…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates

Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty

Steven S. Overman, MD, MPH • illustrations by Alice C. Gray  |  November 16, 2015

I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…

Filed under:Practice SupportProfiles Tagged with:Profileretirementrheumatologistrheumatology practice

FDA Warns ‘Don’t Use Tramadol in Children’ & More

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2015

New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…

Filed under:Drug Updates

Ustekinumab Can Be Used to Safely Treat Teens & More

Michele B. Kaufman, PharmD, BCGP  |  October 7, 2015

A recent study showed ustekinumab can be used to treat teens with moderate to severe psoriasis. Also, Phase 2 trials for an analgesic combination drug show it holds promise for reducing post-operative pain…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:AdolescentsanalgesicBiologics & BiosimilarsPainustekinumab

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences